banner
Enzymatic Release of O-Glycosylated Protein

Enzymatic Release of O-Glycosylated Protein

Since O-Glycosylation occurs in all domains of life, the enzymatic release of O-glycosylated protein is a key segment in glycomics research. CD BioGlyco integrates various advanced technologies to develop an efficient and accurate release strategy of O-glycosylated proteins. Welcome clients from all over the world to cooperate with us!

O-Glycosylated Protein

Glycoproteins are proteins that contain oligosaccharide chains (glycans) covalently linked to amino acid side chains. The most common types of glycoproteins are N-linked and O-linked glycoproteins, which differ by structural differences. Glycans are attached to specific amino acid residue side chains of proteins in a co-translational or post-translational manner, a process known as glycosylation. These post-translationally linked glycans have multiple roles, such as cell recognition, adhesion, signaling, and more. O-Glycosylation is a post-translational event in which the carbohydrate is covalently attached to the hydroxyl group of serine (Ser) or threonine (Thr). O-Glycosylation provides ligands for selectins, resists proteolysis, and is involved in recognition phenomena. O-Glycoproteins change their glycosylation patterns when expressed in new cellular systems resulting in impaired protein function. In addition, O-glycosylation has implications for the biotechnology industry. Therefore, it is of interest to know the location and type of O-glycosylation in a given glycoprotein.

Various forms of O-glycosylation are abundant in organisms and play important roles in many cellular functions. Changes in O-glycosylation are also closely associated with a variety of diseases, such as Alzheimer's disease, diabetes, and cancer. O-Glycosylation changing of Mucin 1 (MUC1) is one of the striking features of oncogenic mucins. Studies have shown that the cancer-associated glycoform of MUC1 contributes to the progression, invasion, and metastasis of epithelial tumors. In conclusion, understanding these O-glycosylation changes in cancer cells may lead to new diagnostic and therapeutic opportunities.

Key Technologies

  • High-throughput sample preparation: Process many samples simultaneously, efficiently, and with minimal manual intervention.
  • Solid-phase extraction (SPE): Following enzymatic release, the sample contains a complex mixture of the now-free glycans, the deglycosylated protein, and the enzyme itself. SPE is a purification technique used to isolate the glycans of interest from this mixture.
  • Size-exclusion chromatography (SEC): Used as a final cleanup step to ensure that the sample is free from any high-molecular-weight contaminants that could interfere with subsequent analyses.

Enzymatic Release of O-Glycosylated Protein: Advanced Solutions for Glycoproteomics

To better understand these O-glycosylation changes in cancer cells, a reliable method must be identified to separate O-glycosylated proteins from native glycoproteins before analysis. At CD BioGlyco, we have developed an advanced Enzymatic Release platform. We provide clients with efficient and accurate release services of native mucin-type O-glycosylated proteins via O-protease. We high-specifically hydrolyze peptide bonds in proteins at the N-terminus of O-glycans at Ser or Thr to release intact native core 1 O-glycosylated proteins. In addition, we provide clients with fast and sensitive O-glycosylated protein characterization services.

The process of enzymatic release of O-glycosylated protein.Fig.1 The process of enzymatic release of O-glycosylated protein. (CD BioGlyco)

  • Sample Preparation

Upon receipt, samples undergo thorough quality assessment to determine protein concentration, purity, and initial glycosylation status.

  • Enzymatic Digestion

A customized enzyme cocktail is selected based on the target O-glycan type and protein properties. The reaction is then performed at optimized temperature, pH, and incubation time to ensure efficient and complete release of O-glycosylated proteins.

  • Glycan and Protein Separation

After enzymatic digestion, the released O-glycans are separated from the deglycosylated protein and residual byproducts using techniques such as solid phase extraction (SPE) or filtration to obtain highly purified released glycosylated fractions.

  • Glycan Derivatization

To enhance detection signals by mass spectrometry (MS) or chromatography, glycans are labeled with 2-aminobenzamide (2-AB), 2-aminopyridine (2-AP), or permethylation to improve ionization efficiency and chromatographic resolution, resulting in more sensitive and accurate analytical results.

  • Downstream Glycan Analysis

Structural elucidation and quantification are performed using high-resolution mass spectrometry (MS), while separation and relative quantification are performed using high-performance liquid chromatography (HPLC).

Workflow

Fig.1 Workflow for the enzymatic release of O-glycosylated protein. (CD BioGlyco)

Publication Data

Journal: Cells

IF: 5.2

Published: 2024

Results: This paper explores glycosylation in depth and emphasizes its importance in biological processes and its potential as a disease biomarker. The article details the characteristics of O-glycosylation, including the various original sugars and core structures, as well as the difficulty in predicting O-glycosylation sites due to the lack of clear protein sequence binding motifs. The article also touches on the interaction between N-glycosylation and O-glycosylation, and their combined effects on cellular function, immune response, and biotherapeutic properties. Finally, the article emphasizes the urgent need to fully characterize O-glycoproteins to understand their functional and structural roles.

Applications

  • Identifying novel O-glycosylation-based biomarkers for early disease detection, progression monitoring, and therapeutic response prediction in conditions such as cancer, inflammatory diseases, and neurological disorders.
  • Characterizing O-glycosylation patterns of therapeutic proteins (e.g., antibodies, fusion proteins) to ensure product quality, efficacy, and safety.
  • Investigating the role of O-glycosylation in pathological processes, including host-pathogen interactions, immune evasion, and cellular signaling pathways, provides insights into disease pathogenesis.

Advantages

  • Our proprietary enzyme panels and optimized protocols ensure highly specific and efficient release of O-glycans, minimizing non-specific cleavage and maximizing glycan yield.
  • We prioritize methods that maintain the native structure of released glycans, preventing desialylation, degradation, or rearrangement.
  • Beyond enzymatic release, CD BioGlyco offers a full suite of downstream glycan analysis services, including advanced MS and chromatography.

Frequently Asked Questions

CD BioGlyco is your trusted partner in glycobiology research, offering a comprehensive suite of services from the enzymatic release of O-glycosylated proteins to advanced glycan analysis and complementary solutions. Please feel free to contact us to discuss your specific project needs and provide tailored solutions.

Associated Services

Reference

  1. Helms, A.; Brodbelt, J.S. Mass spectrometry strategies for O-glycoproteomics. Cells. 2024, 13(5): 394. (Open Access)
This service is for Research Use Only, not intended for any clinical use.
Quick Links
Resources

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0